A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-small Cell Lung Cancer (nsclc)
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation. 2) Previously received at least 1 prior EGFR-targeted TKI. 3) EGFR mutation profile determined locally via a Sponsor-approved testing methodology, using either tumor tissue (ideally from a progressing lesion) and/or ctDNA in plasma.
You may not be eligible for this study if the following are true:
-
1) Tumor harbors any additional known primary driver alterations including but not limited to pathologic abnormalities of EGFR exon 20, KRAS, BRAF V600E, NTRK1/2/3, HER2, ALK, ROS1, MET, or RET. 2) NSCLC with mixed squamous cell histology. 3) Central Nervous System (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
